Michiel Simon Van Der Heijden

A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).

Thomas Powles, Alejo Rodríguez‐Vida, Ignacio Durán et al. · Journal of Clinical Oncology · 2018 · 90 citations

Urology, Surgical Oncology, Tumoral Pathology +15

ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer

Guru Sonpavde, Andrea Necchi, Shilpa Gupta et al. · Future Oncology · 2019 · 90 citations · Full text

IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).

Jean Hoffman‐Censits, Petros Grivas, Michiel Simon Van Der Heijden et al. · Journal of Clinical Oncology · 2016 · 84 citations

Immunology, Immunoediting, Pathology +20

Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study.

Thomas Powles, Yohann Loriot, Alain Ravaud et al. · Journal of Clinical Oncology · 2018 · 44 citations

Immunology, Immunotherapy, Pd-l1 Subgroups +20

PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210).

Jonathan E. Rosenberg, Daniel P. Petrylak, Michiel Simon Van Der Heijden et al. · Journal of Clinical Oncology · 2016 · 42 citations

Immunology, Immunoediting, Pathology +26